Collectively, these results indicate that MLN4924 enhances cancer-associated immunosuppression through upregulation of PD-L1, thus compromising its anti-cancer activity, which is overcame by either MEK inhibitor or anti-PD-L1 antibody via PD-L1 targeting. Here, MAP2K7 is linked to cancer.